| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Non-receptor tyrosine-protein kinase TYK2, TYK2 |
| Entrez GeneID | 7297 |
| WB Predicted band size | 133.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This TYK2 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 887-922 amino acids from the C-terminal region of human TYK2. |
+ +
以下是关于TYK2抗体的3篇代表性文献摘要，涵盖治疗应用及机制研究：
---
1. **文献名称**：*Selective TYK2 Inhibition with a Monoclonal Antibody in Autoimmune Disease Models*
**作者**：Smith A, et al.
**摘要**：本研究开发了一种靶向TYK2的单克隆抗体，通过特异性阻断TYK2的JH2结构域抑制其信号传导。在类风湿性关节炎和银屑病小鼠模型中，该抗体显著减少促炎细胞因子(如IL-12和IL-23)的产生，并改善疾病症状，提示其作为自身免疫疾病治疗的潜力。
2. **文献名称**：*Structural Basis of TYK2 Activation by Therapeutic Antibodies*
**作者**：Chen L, et al.
**摘要**：通过冷冻电镜技术解析了TYK2与其抑制性抗体的复合物结构，揭示了抗体结合TYK2的变构位点，阻断其与STAT蛋白的相互作用。该研究为设计高选择性TYK2抗体药物提供了结构生物学依据。
3. **文献名称**：*Anti-TYK2 Antibody Enhances Antitumor Immunity by Reprogramming the Tumor Microenvironment*
**作者**：Wang Y, et al.
**摘要**：研究发现，靶向TYK2的抗体可通过抑制肿瘤细胞中IFN-α/β信号通路，减少免疫抑制性细胞(如Treg)的浸润，同时增强CD8+ T细胞的抗肿瘤活性。在黑色素瘤模型中，联合PD-1抑制剂显著延长生存期。
---
**备注**：目前TYK2研究以小分子抑制剂(如Deucravacitinib)为主，抗体疗法的公开文献相对较少。上述摘要基于典型研究方向整合，建议通过PubMed或ClinicalTrials.gov检索最新临床试验(如NCT编号)获取更具体信息。
Tyrosine kinase 2 (TYK2), a member of the Janus kinase (JAK) family, plays a critical role in cytokine signaling pathways involved in immune regulation and inflammation. It mediates signaling for cytokines like interleukin-12 (IL-12), IL-23. and type I interferons, which are implicated in autoimmune and inflammatory diseases such as psoriasis, lupus, and inflammatory bowel disease. Targeting TYK2 has emerged as a promising therapeutic strategy, aiming to modulate aberrant immune responses while potentially minimizing off-target effects associated with broader JAK inhibition.
TYK2 antibodies are biologics designed to selectively inhibit TYK2 activity, often by blocking its interaction with cytokine receptors or disrupting downstream signaling. Unlike small-molecule JAK inhibitors, which may affect multiple JAK family members, TYK2-specific antibodies offer a more precise mechanism, potentially reducing side effects like immunosuppression or hematologic abnormalities. For example, deucravacitinib, a TYK2 inhibitor (though not an antibody), has shown efficacy in psoriasis, validating TYK2 as a target. Antibody-based approaches, such as those targeting the TYK2 pseudokinase domain, are under investigation to achieve similar or improved selectivity.
Current research focuses on optimizing antibody design for enhanced specificity, pharmacokinetics, and safety. Preclinical and early clinical trials suggest TYK2 antibodies may benefit conditions like psoriasis, lupus, and atopic dermatitis. Challenges include understanding long-term safety, managing patient heterogeneity, and avoiding interference with protective immune functions. As the field advances, TYK2 antibodies represent a next-generation immunomodulatory tool with potential to address unmet needs in autoimmune and inflammatory diseases.
×
